Nexstim H2’21 Report: Follow up Comment

Redeye is encouraged by the continued momentum in Nexstim and path towards profitability, although with a somewhat new focus following the recent licensing agreement. We slightly increase our base case to SEK 67,5 per share but could adjust further as we learn more about the plans for collaborator Magnus Medical.


Fredrik Thor

Sign up for free to continue

Already a member?

Sign in

Disclosures and disclaimers

Premium Plan required to unlock

Unlock companies to access

more high quality research.